+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Ragweed Pollen Allergy - Pipeline Review, H2 2020

  • ID: 5146879
  • Drug Pipelines
  • August 2020
  • Region: Global
  • 35 pages
  • Global Markets Direct

FEATURED COMPANIES

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Polyrizon Ltd
  • MORE
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Summary

The publisher's latest Pharmaceutical and Healthcare disease pipeline guide Ragweed Pollen Allergy - Pipeline Review, H2 2020, provides an overview of the Ragweed Pollen Allergy (Immunology) pipeline landscape.

Ragweed allergy occurs when ragweed pollen in the air enters the nose and throat of people who are allergic to that pollen, it can cause allergy and asthma symptoms. Symptoms include sneezing, runny or stuffy nose, itchy throat or inside of ears, hives, and swollen eyelids and itchy eyes. Treatment includes decongestant, antihistamine and nasal corticosteroid.

Report Highlights

The publisher's Pharmaceutical and Healthcare latest pipeline guide Ragweed Pollen Allergy - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Ragweed Pollen Allergy (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ragweed Pollen Allergy (Immunology) pipeline guide also reviews the key players involved in therapeutic development for Ragweed Pollen Allergy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Preclinical and Unknown stages are 1, 1, 2 and 1 respectively.

Ragweed Pollen Allergy (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ragweed Pollen Allergy (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Ragweed Pollen Allergy (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ragweed Pollen Allergy (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ragweed Pollen Allergy (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ragweed Pollen Allergy (Immunology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize the emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ragweed Pollen Allergy (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ragweed Pollen Allergy (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Polyrizon Ltd
  • MORE
Introduction

Report Coverage
  • Ragweed Pollen Allergy - Overview
  • Ragweed Pollen Allergy - Therapeutics Development
Pipeline Overview
  • Pipeline by Companies
  • Products under Development by Companies
Ragweed Pollen Allergy - Therapeutics Assessment
  • Assessment by Route of Administration
  • Assessment by Molecule Type
Ragweed Pollen Allergy - Companies Involved in Therapeutics Development
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Polyrizon Ltd
Ragweed Pollen Allergy - Drug Profiles
  • Allergan for Ragweed Pollen Allergy - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BM-34 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • PL-101 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pollinex Ragweed - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • short ragweed pollen (Ambrosia artemisiifolia) allergen extract ODT - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
Ragweed Pollen Allergy - Dormant Projects
  • Ragweed Pollen Allergy - Discontinued Products
  • Ragweed Pollen Allergy - Product Development Milestones
Featured News & Press Releases
  • Nov 08, 2019: ALK to present new phase 3 data demonstrating the efficacy and safety of Ragwitek (short ragweed pollen allergen extract tablet for sublingual use 12 Amb a 1-U) Sublingual Allergy Immunotherapy (SLIT)-Tablets in pediatric patients at ACAAI 2019 Annual Scientific Meeting
  • Feb 16, 2017: ALK submits registration application for ragweed SLIT-tablet in Europe
  • Dec 19, 2014: Anergis Granted U.S. Patent for Ragweed Allergy Vaccine AllerR
  • May 15, 2014: Ragwitek, An Allergy Immunotherapy Tablet For The Treatment Of Signs And Symptoms Of Ragweed Allergy, Is Now Available In Canada
  • Apr 17, 2014: FDA Approves Merck’s RAGWITEK Sublingual Tablet as Immunotherapy to Treat Short Ragweed Pollen-Induced Allergic Rhinitis with or without Conjunctivitis in Adults
  • Jan 24, 2014: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the ragweed sublingual tablet
  • May 08, 2013: Merck Announces FDA Acceptance Of Biologics License Application For Investigational Ragweed Pollen Sublingual Allergy Immunotherapy Tablet
  • Mar 11, 2013: ALK’s Partner Merck Submits BLA To FDA For Marketing Authorization For Ragweed AIT
  • Feb 22, 2013: Merck To Present New Data Analyses Of Its Investigational Ragweed Pollen And Grass Pollen Allergy Immunotherapy Tablets At 2013 AAAAI Annual Meeting
  • Feb 21, 2013: Anergis To Present Preclinical Data On Ragweed Allergy Vaccine Candidate AllerR At AAAAI 2013 Annual Meeting
  • Jun 14, 2012: Anergis Reaches Several Preclinical Development Milestones With Ragweed Pollen Vaccine
Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact
  • Disclaimer
List of Tables
  • Number of Products under Development for Ragweed Pollen Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Products under Development by Companies, H2 2020
  • Number of Products by Stage and Route of Administration, H2 2020
  • Number of Products by Stage and Molecule Type, H2 2020
  • Ragweed Pollen Allergy - Pipeline by ALK-Abello AS, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Anergis SA, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Biomay AG, H2 2020
  • Ragweed Pollen Allergy - Pipeline by Polyrizon Ltd, H2 2020
  • Ragweed Pollen Allergy - Dormant Projects, H2 2020
  • Ragweed Pollen Allergy - Discontinued Products, H2 2020
List of Figures
  • Number of Products under Development for Ragweed Pollen Allergy, H2 2020
  • Number of Products under Development by Companies, H2 2020
  • Number of Products by Routes of Administration, H2 2020
  • Number of Products by Stage and Routes of Administration, H2 2020
  • Number of Products by Molecule Types, H2 2020
  • Number of Products by Stage and Molecule Types, H2 2020
Note: Product cover images may vary from those shown
  • ALK-Abello AS
  • Allergy Therapeutics Plc
  • Anergis SA
  • Biomay AG
  • Polyrizon Ltd
Note: Product cover images may vary from those shown
Adroll
adroll